Facts and figures

in page functions

The evidence is clear: vaccines are one of the most cost-effective investments in health and development in history. Gavi helps save children’s lives and protect people’s health by increasing access to immunisation in poor countries.

7 million deaths averted

Since its launch in 2000, Gavi has helped developing countries to prevent more than 7 million future deaths from hepatitis B, Haemophilus influenzae type b (Hib), measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever.

Source: Gavi/Bill & Melinda Gates Foundation

500 million children immunised

Since 2000, Gavi support has contributed to the immunisation of an additional 500 million children.


Reaching 76% coverage with DTP3

DTP3 coverage reached 76% in 2013 in the 73 countries supported by the Alliance.


Almost 4 million deaths averted between 2011 and 2015

The Alliance’s support for vaccines will contribute to averting an estimated 3.9 million future deaths between 2011 and 2015.

Source: Gavi

Nearly a quarter of a billion immunised by 2015

Gavi support will assist countries to immunise a further 243 million children between 2011 and 2015.

Source: Gavi

11 million children vaccinated against pneumococcal disease

Gavi support had contributed to immunising 11 million children against pneumococcal disease by the end of 2013.


Over 4 million children vaccinated against rotavirus

Gavi support had contributed to immunising more than four million children against rotavirus diarrhoea by the end of 2013.


More than 150 million people immunised against meningitis A

By the end of 2013, 11 countries in the African meningitis belt had collectively immunised 153 million people against meningitis A with support from the Vaccine Alliance.


Investing in immunisation is one of the most cost-effective ways of improving living standards, health and the global economy.

100 million illness cases averted

Vaccines have a long-term positive impact beyond health outcomes. Expanded immunisation in Gavi-suported countries from 2016 to 2020 could deliver more than 100 million illness cases averted. This will reduce the burden of care on parents, improving their productivity and freeing them from crippling medical costs. And by protecting children from infectious diseases, vaccines will also help raise IQ levels.

Source: Lee LA et al. The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the Gavi. Vaccine 2013

US$ 80-100 billion in economic benefits

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

Recognising the need to attract new sources of funding to meet accelerating country demand, Gavi held its first ever pledging conference in June 2011, raising US$ 4.3 billion from donors.

US$ 7.3 billion in donor support 2011-2015

Top 10 donors: UK: 2.36b; BMGF: 1.30b; Norway: 773m; US: 533m; France: 462m; Italy: 442m; Netherlands: 240m; Sweden: 268m; Australia: 232m; Germany: 189m (Contributions in US$ as at Dec 2013)

US$ 2.3 billion from IFFIm

As of December 2013, IFFIm has contributed US$ 2.3 billion to Gavi to fund vaccines and other programmes, and IFFIm’s "vaccine bonds" have raised US$ 4.55 billion on the capital markets since 2006.

US$ 8.7 billion committed to countries

By the end of June 2014, the Vaccine Alliance has committed US$ 8.7 billion in programme support until 2017 to the world’s poorest countries.

More than 60 countries co-financing

For 2013, more than 60 countries were co-financing new and underused vaccines supplied by the Vaccine Alliance. Their contributions totalled US$ 70 million.

Gavi supports 73 countries

Gavi support is available to the 73 poorest countries in the world. By the end of 2013, 22 countries were projected to graduate from Gavi’s support by 2020.

While equity between high- and low-income countries is at the core of the Gavi’s mission, equity within countries is equally critical. Gavi strives to ensure that the poorest and most vulnerable populations are reached.

1.5 million children under five lose their lives to vaccine preventable diseases every year.

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

Almost 22 million under-immunised

Nearly 22 million [21.8 million] infants remain under-immunised in the world each year.


Almost 25% not immunised

In total, 24% of children in Gavi-supported countries are not being vaccinated.


Nearly one third of child deaths are due to pneumonia and diarrhoea

Pneumonia and diarrhoea account for 30% - nearly one third - of child deaths in Gavi-supported countries.


One woman dies every 2 minutes from cervical cancer

One woman dies from cervical cancer every two minutes - or 275,000 a year- over 85% in the developing world.

70% of cervical cancer cases can be prevented with HPV vaccine.

Source: WHO

90 thousand born with birth defects due to rubella

Every year, 90,000 babies in Gavi countries are born with severe birth defects known as Congenital Rubella Syndrome (CRS) because their mothers were infected with rubella during pregnancy.

Source: WHO

Pneumococcal vaccine: more than 90% reduction to US$ 3.50 per dose

Through the Advance Market Commitment, pneumococcal vaccines are available to GAVI-eligible countries at no more than US$ 3.50 per dose, a more than 90% reduction compared with the public price in the United States. In 2013, Gavi secured a lowest price offer for pneumococcal vaccines of US$ 3.30 per dose from 2014 onwards.

Pentavalent (DTP-hep B-Hib) vaccine: a reduction of more than 40% to US$ 2.04 per dose

Over the course of a decade, the weighted average price (WAP) of pentavalent vaccine dropped by 43% from US$ 3.56 per dose in 2003 to US$ 2.04 per dose in 2013, with a lowest-ever price of US$ 1.19 from one supplier in 2013.

Rotavirus vaccine: 67% reduction to US$ 2.50

As a result of long-term supply agreements with manufacturers signed in 2012, Gavi buys the bulk of its rotavirus vaccine doses at US$ 2.50 (US$ 5.0 per course), a two-thirds reduction compared to the previous lowest price offered to Gavi of US$ 7.50 a dose (US$15 a course), and will have an expected market impact valued at US$ 650 million.

Human papillomavirus (HPV) vaccine: two-thirds reduction to US$ 4.50

Gavi works with manufacturers to bring down HPV prices. In 2013, a new price of US$ 4.50 per dose was agreed, a two-thirds reduction on the current lowest public price.

From 5 to 13 vaccine manufacturers supplying Gavi – from 1 to 5 based in middle-income countries

2001: 5 vaccine manufacturers - 1 based in a middle-income country.

2013: 13 vaccine manufacturers – 6 based in middle-income countries.

close icon

modal window here